Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
22 Jun 2021 According to a AMRA Medical media release, the study was conducted by the researchers from the University Hospitals Cleveland Medical Center and this research was supported by an investigator-initiated grant, for which Novo Nordisk provided funding and study drug.
22 Jun 2021 According to a AMRA Medical media release, data from this trial will be presented at the American Diabetes Association (ADA) virtual conference 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com